Aclaris Therapeutics (ACRS) Scheduled to Post Earnings on Tuesday

Aclaris Therapeutics (NASDAQ:ACRS) will be issuing its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Aclaris Therapeutics had a negative return on equity of 64.56% and a negative net margin of 283.15%. The company had revenue of $17.57 million for the quarter, compared to analyst estimates of $3.96 million. On average, analysts expect Aclaris Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aclaris Therapeutics Stock Up 3.8 %

Shares of ACRS opened at $1.36 on Friday. The firm’s fifty day moving average is $1.23 and its two-hundred day moving average is $1.62. The stock has a market cap of $96.91 million, a PE ratio of -1.07 and a beta of 0.23. Aclaris Therapeutics has a 52-week low of $0.59 and a 52-week high of $11.12.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ACRS. StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. HC Wainwright lowered shares of Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, January 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a research report on Thursday, January 11th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Friday, January 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $22.25.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.